GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transcenta Holding Ltd (HKSE:06628) » Definitions » Median PS Value

Transcenta Holding (HKSE:06628) Median PS Value : HK$0.00 (As of Apr. 28, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Transcenta Holding Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Transcenta Holding's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was HK$0.03. Transcenta Holding's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is HK$0.00.

As of today (2025-04-28), Transcenta Holding's share price is HK$1.26. Transcenta Holding's Median PS Value is HK$0.00. Therefore, Transcenta Holding's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Transcenta Holding's Median PS Value or its related term are showing as below:

HKSE:06628's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.66
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Transcenta Holding Median PS Value Historical Data

The historical data trend for Transcenta Holding's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transcenta Holding Median PS Value Chart

Transcenta Holding Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Median PS Value
Get a 7-Day Free Trial - - - - -

Transcenta Holding Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Transcenta Holding's Median PS Value

For the Biotechnology subindustry, Transcenta Holding's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Transcenta Holding's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Transcenta Holding's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Transcenta Holding's Price-to-Median-PS-Value falls into.


;
;

Transcenta Holding Median PS Value Calculation

Transcenta Holding's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=0.03*0
=0.00

10-Year Median PS Ratio is 0.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Transcenta Holding's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was HK$0.03.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Transcenta Holding  (HKSE:06628) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Transcenta Holding's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=1.26/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Transcenta Holding Median PS Value Related Terms

Thank you for viewing the detailed overview of Transcenta Holding's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Transcenta Holding Business Description

Traded in Other Exchanges
N/A
Address
B6-501, 218 Xinghu Street, Biobay, Suzhou, CHN, 215123
Transcenta Holding Ltd is a clinical-stage biopharmaceutical company with fully integrated capacities in discovery, research, development, and manufacturing. It is developing nine therapeutic antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders. Geographically the company operates in China (the PRC) and the USA.
Executives
Qian Xueming 2101 Beneficial owner
Shi Xiaohong 2501 Other
Lav Corporate Gp, Ltd. 2201 Interest of corporation controlled by you
Lav Gp Iii, L.p. 2201 Interest of corporation controlled by you
Lav Biosciences Fund Iii, L.p. 2101 Beneficial owner
Shi Yi 2201 Interest of corporation controlled by you
Lav Asset Management (hong Kong) Limited 2102 Investment manager
Fullerton Management Pte Ltd
Temasek Life Sciences Private Limited
Tls Beta Pte. Ltd.
Hsbc Trust Company (delaware), N.a. 2301 Trustee
Success Link International L.p. 2101 Beneficial owner
Temasek Holdings (private) Limited
Lav Vitality Limited 2101 Beneficial owner
Zhong Guo Guo You Qi Ye Jie Gou Tiao Zheng Ji Jin Gu Fen You Xian Gong Si 2501 Other

Transcenta Holding Headlines

No Headlines